scholarly journals Polarization of intestinal tumour-associated macrophages regulates the development of schistosomal colorectal cancer

2021 ◽  
Vol 12 (4) ◽  
pp. 1033-1041
Author(s):  
Zijian Wang ◽  
Zhixiang Du ◽  
Haoyu Sheng ◽  
Xiuliang Xu ◽  
Wenjie Wang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Intestinal Tumour

scholarly journals Sensitive high-throughput assays for tumour burden reveal the response of a Drosophila melanogaster model of colorectal cancer to standard chemotherapies

2021 ◽  
Author(s):  
Jamie Adams ◽  
Andreu Casali ◽  
Kyra Campbell
Keyword(s):  
Colorectal Cancer ◽  
Drosophila Melanogaster ◽  
High Throughput ◽  
Tumour Progression ◽  
Luciferase Reporter ◽  
Tumour Burden ◽  
Epithelial Cancers ◽  
Activating Mutations ◽  
Intestinal Tumour ◽  
Ras Signalling

Drosophila melanogaster (Drosophila) models of cancer are emerging as powerful tools to investigate the basic mechanisms underlying tumour progression and identify novel therapeutics. Rapid and inexpensive, it is possible to carry out genetic and drug screens at a far larger scale than in vertebrate organisms. Such whole-organism-based drug screens permits assessment of drug absorption and toxicity, reducing the possibility of false positives. Activating mutations in the Wnt and Ras signalling pathways are common in many epithelial cancers, and when driven in the adult Drosophila midgut, it induces aggressive intestinal tumour-like outgrowths that recapitulate many aspects of human colorectal cancer (CRC). Here we have taken a Drosophila CRC model in which tumourous cells are marked with both GFP and luciferase reporter genes, and developed novel high-throughput assays for quantifying tumour burden. Leveraging these assays, we find that the Drosophila CRC model responds rapidly to treatment with standard CRC-drugs, opening the door to future rapid genetic and drug screens.

scholarly journals Sensitive High-Throughput Assays for Tumour Burden Reveal the Response of a Drosophila melanogaster Model of Colorectal Cancer to Standard Chemotherapies

2021 ◽  
Vol 22 (10) ◽  
pp. 5101
Author(s):  
Jamie Adams ◽  
Andreu Casali ◽  
Kyra Campbell
Keyword(s):  
Colorectal Cancer ◽  
Drosophila Melanogaster ◽  
High Throughput ◽  
Tumour Progression ◽  
Luciferase Reporter ◽  
Tumour Burden ◽  
Epithelial Cancers ◽  
Activating Mutations ◽  
Intestinal Tumour ◽  
Ras Signalling

Drosophila melanogaster (Drosophila) models of cancer are emerging as powerful tools to investigate the basic mechanisms underlying tumour progression and identify novel therapeutics. Rapid and inexpensive, it is possible to carry out genetic and drug screens at a far larger scale than in vertebrate organisms. Such whole-organism-based drug screens permits assessment of drug absorption and toxicity, reducing the possibility of false positives. Activating mutations in the Wnt and Ras signalling pathways are common in many epithelial cancers, and when driven in the adult Drosophila midgut, it induces aggressive intestinal tumour-like outgrowths that recapitulate many aspects of human colorectal cancer (CRC). Here we have taken a Drosophila CRC model in which tumourous cells are marked with both GFP and luciferase reporter genes, and developed novel high-throughput assays for quantifying tumour burden. Leveraging these assays, we find that the Drosophila CRC model responds rapidly to treatment with standard CRC-drugs, opening the door to future rapid genetic and drug screens.

Deletion mapping on chromosome 6 in colorectal cancer associated with ulcerative colitis

2001 ◽  
Vol 120 (5) ◽  
pp. A121-A122
Author(s):  
T EZAKI ◽  
M WATANABE ◽  
S FUNAKOSHI ◽  
M NAGANUMA ◽  
T AZUMA ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Ulcerative Colitis ◽  
Deletion Mapping ◽  
Chromosome 6

Predicting adherence to colorectal cancer surveillance after plypectomy

2001 ◽  
Vol 120 (5) ◽  
pp. A602-A602
Author(s):  
S RAWL ◽  
S BLACKBURN ◽  
L HACKWARD ◽  
N FINEBERG ◽  
T IMPERIALE ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Surveillance ◽  
Colorectal Cancer Surveillance

Urokinase type plasminogen activator and inhibitor type-1 plasma levels in colorectal cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A599-A600 ◽  
Author(s):  
L HERSZENYI ◽  
F FARINATI ◽  
G ISTVAN ◽  
M PAOLI ◽  
G ROVERONI ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Plasminogen Activator ◽  
Plasma Levels ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Inhibitor Type

A panel of mono- and dinucleotide microsatellite markers is required for reliable determination of the MSI status in colorectal cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A599-A599
Author(s):  
C ARNOLD ◽  
A GOEL ◽  
J CARETHERS ◽  
L WASSERMAN ◽  
C COMPTON ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Microsatellite Markers ◽  
Reliable Determination

Use of plasma MMP-2 to measure response to surgery and chemoradiotherapy in colorectal cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A159-A159
Author(s):  
M TUTTON ◽  
M GEORGE ◽  
S ECCLES ◽  
I SWIFT ◽  
M ABULAFI
Keyword(s):  
Colorectal Cancer

Barriers to colorectal cancer (CRS) screening in minority communities: inadequate knowledge of guidelines by physicians in training

2001 ◽  
Vol 120 (5) ◽  
pp. A604-A604
Author(s):  
M GENNARELLI ◽  
L JANDORF ◽  
C CROMWELL ◽  
H VALDIMARSDOTTIR ◽  
W REDD ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Minority Communities ◽  
Inadequate Knowledge
Sign in / Sign up

Export Citation Format

Share Document